EvoEndo’s system uses a single-use, flexible gastroscope and provides virtual reality entertainment for patients to allow the procedure to be performed without anesthesia or sedation.
Distribution will begin once the companies receive FDA 510(k) clearance, which requires companies to notify the federal agency of its intent to market a product at least 90 days in advance.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
